190 related articles for article (PubMed ID: 34585994)
21. Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.
Hwang HS; Han AR; Lee JY; Park GS; Min WS; Kim HJ
Immunol Invest; 2019 Jan; 48(1):96-105. PubMed ID: 30204524
[TBL] [Abstract][Full Text] [Related]
22. Scrutinizing the Expression and Blockade of Inhibitory Molecules Expressed on T Cells from Acute Myeloid Leukemia Patients.
Abdolmaleki M; Mojtabavi N; Zavvar M; Vaezi M; Noorbakhsh F; Nicknam MH
Iran J Allergy Asthma Immunol; 2018 Jun; 17(3):265-273. PubMed ID: 29908544
[TBL] [Abstract][Full Text] [Related]
23. Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapy.
Wu M; Wu A; Zhang X; Li Y; Li B; Jin S; Dong Q; Niu X; Zhang L; Zhou X; Du J; Wu Y; Zhai W; Zhou X; Qiu L; Gao Y; Zhao W
Biochem Pharmacol; 2023 Jun; 212():115583. PubMed ID: 37148978
[TBL] [Abstract][Full Text] [Related]
24. Lactate acid promotes PD-1
Zhang Y; Huang Y; Hong Y; Lin Z; Zha J; Zhu Y; Li Z; Wang C; Fang Z; Zhou Z; Peng Y; Yu X; Liu L; Xu B
Int Immunopharmacol; 2024 Mar; 130():111765. PubMed ID: 38447414
[TBL] [Abstract][Full Text] [Related]
25. One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia.
Wang Z; Chen J; Wang M; Zhang L; Yu L
Front Immunol; 2021; 12():618710. PubMed ID: 33868234
[TBL] [Abstract][Full Text] [Related]
26. STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia.
Huang ZW; Zhang XN; Zhang L; Liu LL; Zhang JW; Sun YX; Xu JQ; Liu Q; Long ZJ
Signal Transduct Target Ther; 2023 Sep; 8(1):391. PubMed ID: 37777506
[TBL] [Abstract][Full Text] [Related]
27. Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification.
Li C; Chen X; Yu X; Zhu Y; Ma C; Xia R; Ma J; Gu C; Ye L; Wu D
Int J Clin Exp Pathol; 2014; 7(10):6880-8. PubMed ID: 25400771
[TBL] [Abstract][Full Text] [Related]
28. Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia.
Irani YD; Kok CH; Clarson J; Shanmuganathan N; Branford S; Yeung DT; Ross DM; Hughes TP; Yong ASM
Blood Adv; 2023 Jun; 7(11):2364-2374. PubMed ID: 36622326
[TBL] [Abstract][Full Text] [Related]
29. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
[TBL] [Abstract][Full Text] [Related]
30. Expression of RANK-L and in part of PD-1 on blasts in patients with acute myeloid leukemia correlates with prognosis.
Schmohl JU; Nuebling T; Wild J; Kroell T; Kanz L; Salih HR; Schmetzer H
Eur J Haematol; 2016 Dec; 97(6):517-527. PubMed ID: 27096305
[TBL] [Abstract][Full Text] [Related]
31. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT.
Noviello M; Manfredi F; Ruggiero E; Perini T; Oliveira G; Cortesi F; De Simone P; Toffalori C; Gambacorta V; Greco R; Peccatori J; Casucci M; Casorati G; Dellabona P; Onozawa M; Teshima T; Griffioen M; Halkes CJM; Falkenburg JHF; Stölzel F; Altmann H; Bornhäuser M; Waterhouse M; Zeiser R; Finke J; Cieri N; Bondanza A; Vago L; Ciceri F; Bonini C
Nat Commun; 2019 Mar; 10(1):1065. PubMed ID: 30911002
[TBL] [Abstract][Full Text] [Related]
32. Functional exhaustion of CD4
Ozkazanc D; Yoyen-Ermis D; Tavukcuoglu E; Buyukasik Y; Esendagli G
Immunology; 2016 Dec; 149(4):460-471. PubMed ID: 27565576
[TBL] [Abstract][Full Text] [Related]
33. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment.
Krönig H; Kremmler L; Haller B; Englert C; Peschel C; Andreesen R; Blank CU
Eur J Haematol; 2014 Mar; 92(3):195-203. PubMed ID: 24175978
[TBL] [Abstract][Full Text] [Related]
34. Increased exhausted CD8
Tan J; Chen S; Huang J; Chen Y; Yang L; Wang C; Zhong J; Lu Y; Wang L; Zhu K; Li Y
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e266-e274. PubMed ID: 29943497
[TBL] [Abstract][Full Text] [Related]
35. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
36. PD-1/PD-L1 Interaction Regulates BCL2, KI67, BAX, and CASP3, Altering Proliferation, Survival, and Apoptosis in Acute Myeloid Leukemia.
Soltani M; Vosoughi M; Ganjalikhani-Hakemi M; Shapoorian H; Beshkar P; Eskandari N; Ghezelbash B
Iran J Allergy Asthma Immunol; 2023 Oct; 22(5):495-503. PubMed ID: 38085150
[TBL] [Abstract][Full Text] [Related]
37. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia.
Zahran AM; Mohammed Saleh MF; Sayed MM; Rayan A; Ali AM; Hetta HF
Cancer Biomark; 2018; 22(3):587-595. PubMed ID: 29843224
[TBL] [Abstract][Full Text] [Related]
38. Programmed Death Ligand-1 is Frequently Expressed in Primary Acute Myeloid Leukemia and B-Acute Lymphoblastic Leukemia.
Hamdan SO; Sughayer M; Khader M; Tbakhi A; Khudirat S; Hejazi A; AlRyalat S; Bustami N; Aladily TN
Clin Lab; 2022 Apr; 68(4):. PubMed ID: 35443604
[TBL] [Abstract][Full Text] [Related]
39. TIM-3 Expression Level on AML Blasts Correlates With Presence of Core Binding Factor Translocations Rather Than Clinical Outcomes.
Hong J; Xia L; Huang Z; Yuan X; Liang X; Dai J; Wu Z; Liang L; Ruan M; Long Z; Cheng X; Chen X; Ni J; Ge J; Li Q; Zeng Q; Xia R; Wang Y; Yang M
Front Oncol; 2022; 12():879471. PubMed ID: 35494006
[TBL] [Abstract][Full Text] [Related]
40. THE ROLE GENE EXPRESSION OF PD-1 AND PD-L1 IN NEWELY DIAGNOSED AND TREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA.
Al-Saedi S; Hamzah I
Georgian Med News; 2023; (340-341):25-29. PubMed ID: 37805869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
